Slc17A8 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SLC17A8 Gene is involved in biological pathways relevant to neurodegenerative diseases. It plays important roles in neuronal function, cellular signaling, ion transport, protein homeostasis, or stress response mechanisms.
Dysregulation or mutations in this gene contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
SLC17A8 encodes vesicular glutamate transporter 3 (VGLUT3), responsible for packaging glutamate into synaptic vesicles in neurons. Unlike other VGLUTs (VGLUT1 and VGLUT2), VGLUT3 is expressed in neurons that are not primarily glutamatergic, leading to its role as a "cotransmitter" system.[1]
VGLUT3 is unique among VGLUTs because it is expressed in monoaminergic and cholinergic neurons, where it packages glutamate as a cotransmitter alongside dopamine, serotonin, or acetylcholine. This glutamatergic cotransmission modulates synaptic signaling and has important implications for neurodegenerative diseases.[2]
VGLUT3 plays a complex role in PD. While VGLUT2 (SLC17A6) is more abundantly expressed in the substantia nigra, VGLUT3 is expressed in a subset of dopaminergic neurons. Altered VGLUT3 expression may affect dopamine-glutamate cotransmission and contribute to excitotoxicity in PD.[3]
SLC17A8 mutations cause autosomal dominant hearing loss (DFNA25). The gene is highly expressed in inner hair cells of the cochlea, where it is essential for glutamatergic neurotransmission from hair cells to spiral ganglion neurons.[4]
Recessive SLC17A8 mutations cause a severe auditory neuropathy phenotype in infants, characterized by absent or abnormal auditory brainstem responses despite preserved outer hair cell function.[5]
VGLUT3 has a unique expression pattern:
VGLUT3 is often coexpressed with other neurotransmitter transporters, supporting its role as a cotransmitter.[6]
The study of Slc17A8 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Gras C, et al. J Neurosci. 2008;28(36):8940-8950.
[2] Dal Bo G, et al. J Neurosci. 2004;24(26):5789-5799.
[3] Nelson AB, et al. Brain Res. 2014;1587:68-76.
[4] Lucas-Herald AK, et al. Brain. 2012;135(Pt 10):2943-2953.
[5] Kim J, et al. Hum Genet. 2014;133(5):599-611.